SCI Pharmtech, Inc. (4119.TW)
TWD 68.3
(-2.29%)
TWD 68.3
(-2.29%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.59 Billion TWD | 19.49% |
| 2022 | 1.33 Billion TWD | 53.15% |
| 2021 | 869.26 Million TWD | -30.33% |
| 2020 | 1.24 Billion TWD | 105.61% |
| 2019 | 606.83 Million TWD | 4.84% |
| 2018 | 578.84 Million TWD | 58.21% |
| 2017 | 365.88 Million TWD | -23.68% |
| 2016 | 479.42 Million TWD | -31.02% |
| 2015 | 695.01 Million TWD | -30.12% |
| 2014 | 994.63 Million TWD | 1.02% |
| 2013 | 984.62 Million TWD | 206.62% |
| 2012 | 321.12 Million TWD | -16.65% |
| 2011 | 385.26 Million TWD | 3.18% |
| 2010 | 373.37 Million TWD | 74.21% |
| 2009 | 214.32 Million TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.55 Billion TWD | -2.13% |
| 2024 Q2 | 1.78 Billion TWD | 14.46% |
| 2023 Q4 | 1.59 Billion TWD | 11.5% |
| 2023 Q2 | 1.3 Billion TWD | -14.46% |
| 2023 Q3 | 1.42 Billion TWD | 9.2% |
| 2023 FY | 1.59 Billion TWD | 19.49% |
| 2023 Q1 | 1.52 Billion TWD | 14.71% |
| 2022 Q4 | 1.33 Billion TWD | 25.56% |
| 2022 Q3 | 1.06 Billion TWD | 0.49% |
| 2022 FY | 1.33 Billion TWD | 53.15% |
| 2022 Q2 | 1.05 Billion TWD | 3.42% |
| 2022 Q1 | 1.02 Billion TWD | 17.36% |
| 2021 Q2 | 913.72 Million TWD | -17.84% |
| 2021 Q4 | 869.26 Million TWD | -4.48% |
| 2021 FY | 869.26 Million TWD | -30.33% |
| 2021 Q1 | 1.11 Billion TWD | -10.87% |
| 2021 Q3 | 910.06 Million TWD | -0.4% |
| 2020 FY | 1.24 Billion TWD | 105.61% |
| 2020 Q3 | 617.43 Million TWD | -48.5% |
| 2020 Q4 | 1.24 Billion TWD | 102.08% |
| 2020 Q1 | 661.96 Million TWD | 9.08% |
| 2020 Q2 | 1.19 Billion TWD | 81.13% |
| 2019 Q1 | 606.01 Million TWD | 4.69% |
| 2019 FY | 606.83 Million TWD | 4.84% |
| 2019 Q4 | 606.83 Million TWD | 7.66% |
| 2019 Q3 | 563.65 Million TWD | -40.37% |
| 2019 Q2 | 945.2 Million TWD | 55.97% |
| 2018 Q2 | 668.76 Million TWD | 68.25% |
| 2018 Q4 | 578.84 Million TWD | -3.14% |
| 2018 FY | 578.84 Million TWD | 58.21% |
| 2018 Q1 | 397.47 Million TWD | 8.63% |
| 2018 Q3 | 597.58 Million TWD | -10.64% |
| 2017 Q3 | 386.78 Million TWD | -49.1% |
| 2017 FY | 365.88 Million TWD | -23.68% |
| 2017 Q4 | 365.88 Million TWD | -5.4% |
| 2017 Q2 | 759.81 Million TWD | 85.26% |
| 2017 Q1 | 410.13 Million TWD | -14.45% |
| 2016 Q3 | 401.42 Million TWD | -50.09% |
| 2016 Q4 | 479.42 Million TWD | 19.43% |
| 2016 FY | 479.42 Million TWD | -31.02% |
| 2016 Q1 | 705.42 Million TWD | 1.5% |
| 2016 Q2 | 804.23 Million TWD | 14.01% |
| 2015 Q4 | 695.01 Million TWD | -0.4% |
| 2015 Q3 | 697.81 Million TWD | -30.51% |
| 2015 Q2 | 1 Billion TWD | 3.93% |
| 2015 Q1 | 966.23 Million TWD | -2.86% |
| 2015 FY | 695.01 Million TWD | -30.12% |
| 2014 FY | 994.63 Million TWD | 1.02% |
| 2014 Q4 | 994.63 Million TWD | 0.49% |
| 2014 Q3 | 989.79 Million TWD | -15.99% |
| 2014 Q2 | 1.17 Billion TWD | 19.36% |
| 2014 Q1 | 987.02 Million TWD | 0.24% |
| 2013 FY | 984.62 Million TWD | 206.62% |
| 2013 Q1 | 839.75 Million TWD | 161.51% |
| 2013 Q2 | 1 Billion TWD | 19.54% |
| 2013 Q3 | 838.7 Million TWD | -16.45% |
| 2013 Q4 | 984.62 Million TWD | 17.4% |
| 2012 Q4 | 321.12 Million TWD | 9.74% |
| 2012 Q2 | 347.91 Million TWD | 21.95% |
| 2012 FY | 321.12 Million TWD | -16.65% |
| 2012 Q1 | 285.29 Million TWD | -25.95% |
| 2012 Q3 | 292.62 Million TWD | -15.89% |
| 2011 Q1 | 292.25 Million TWD | -21.73% |
| 2011 Q2 | 393.22 Million TWD | 34.55% |
| 2011 Q3 | 374.26 Million TWD | -4.82% |
| 2011 Q4 | 385.26 Million TWD | 2.94% |
| 2011 FY | 385.26 Million TWD | 3.18% |
| 2010 FY | 373.37 Million TWD | 74.21% |
| 2010 Q4 | 373.37 Million TWD | 0.0% |
| 2009 FY | 214.32 Million TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Grape King Bio Ltd | 3.88 Billion TWD | 59.02% |
| Standard Chem & Pharm CO., LTD. | 3.05 Billion TWD | 47.867% |
| Maywufa Company Ltd. | 794.91 Million TWD | -100.121% |
| ScinoPharm Taiwan, Ltd. | 1.35 Billion TWD | -17.215% |
| Lotus Pharmaceutical Co., Ltd. | 15.65 Billion TWD | 89.84% |
| LIWANLI Innovation Co., Ltd. | 50.66 Million TWD | -3040.126% |
| YungShin Global Holding Corporation | 3.59 Billion TWD | 55.78% |
| PhytoHealth Corporation | 79.84 Million TWD | -1892.245% |
| Formosa Laboratories, Inc. | 5.42 Billion TWD | 70.682% |
| PharmaEssentia Corporation | 3.32 Billion TWD | 52.102% |
| Bora Pharmaceuticals Co., LTD. | 13.28 Billion TWD | 88.027% |